spacer
home > ict > autumn 2009 > equipped for success
PUBLICATIONS
International Clinical Trials

Equipped for Success

 

Over recent years, many good articles have been written about outsourcing in clinical studies. Most of these refer to outsourcing of trials by pharma companies to clinical research organisations, and cover all aspects from cost benefit analysis, supplier selection process, scorecards, performance measurement and management of customer and supplier relationships. At the risk of being inundated with responses from readers advising me to the contrary, I cannot recollect reading any articles regarding outsourcing of a company’s medical equipment requirements for clinical studies to a single supplier.

In many ways, this is understandable, as initiation of an outsourcing project is often instigated by senior levels within a business such as board members and directors. For the majority of clinical trials, the total cost of medical equipment is a very low figure, often less than two per cent of the trial cost. For this reason, medical equipment will rarely appear on senior management’s radar unless it has been the cause of serious delays or caused impairment of the results of a trial.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

David Maughan is Managing Director of Medical Equipment Supplies and Management Ltd (MESM), a global supplier of medical equipment to the clinical trials industry. David is also a non-executive director of the Optare Group (bus manufacturer), board member of the Northwest Industrial Development Board and also of the North-west Automotive Alliance. David spent 30 years working in the automotive sector in various procurement roles, the most recent being 10 years as Purchasing Director of Bentley motor cars, part of the VW Group. During that time he was a member of the corporate sourcing committee for all group purchases.

spacer
David Maughan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Moderna Announces FDA Advisory Committee Unanimously Votes in Support of Emergency Use for a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today confirmed that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended that the FDA grant an Emergency Use Authorization (EUA) for a booster dose of the Moderna COVID-19 vaccine.
More info >>

White Papers

Speciality Logistics Outlook 2015

World Courier

To date, there are more than 178,000 registered clinical trials taking place across the globe, and global pharma’s volume has more than doubled over the last decade. With emerging markets showing explosive predictive growth through 2016, shippers and trial sponsors can expect continued regulatory and overall logistics complexities that foster demand for local, inmarket resources across the globe.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement